Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Journal of Clinical Pharmacology|August 14, 1998
AmBisome (liposomal amphotericin B): a comparative reviewG W Boswell, D Buell, I BekerskyCancer Treatment Reports|September 1, 1977
Role of staging in childhood non-Hodgkin's lymphomaN Jaffe, D Buell, J R Cassady, et al.Alimentary Pharmacology & Therapeutics|August 10, 2004
Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agentK Pettengell, J Mynhardt, T Kluyts, et al.Antimicrobial Agents and Chemotherapy|April 4, 1998
Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in ratsG W Boswell, I Bekersky, D Buell, et al.Antimicrobial Agents and Chemotherapy|November 23, 2006
Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adultsJ Keirns, T Sawamoto, M Holum, et al.Pharmaceutical Research|April 17, 2001
Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in ratsI Bekersky, G W Boswell, R Hiles, et al.Pharmaceutical Research|November 26, 1999
Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogsI Bekersky, G W Boswell, R Hiles, et al.Blood|April 1, 1979
Improved prognosis for patients with mediastinal lymphoblastic lymphomaH J Weinstein, Z B Vance, N Jaffe, et al.Antimicrobial Agents and Chemotherapy|March 29, 2005
Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplantJ Hiemenz, P Cagnoni, D Simpson, et al.The Journal of Experimental Medicine|September 1, 1993
Diversification, not use, of the immunoglobulin VH gene repertoire is restricted in DiGeorge syndromeR N Haire, R D Buell, R T Litman, et al.Pageof 2